Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients

Journal Article · · Movement Disorders
DOI:https://doi.org/10.1002/mds.27318· OSTI ID:1437062
 [1];  [2];  [3];  [4];  [5];  [6];  [2];  [7]
  1. Department of Neurology Penn State University‐Milton S. Hershey Medical Center Hershey Pennsylvania United States
  2. Department of Neurology Penn State University‐Milton S. Hershey Medical Center Hershey Pennsylvania United States, Department of Pharmacology Penn State University‐Milton S. Hershey Medical Center Hershey Pennsylvania United States
  3. Department of Radiology Penn State University‐Milton S. Hershey Medical Center Hershey Pennsylvania United States
  4. School of Public Health Shanxi Medical University Taiyuan Shanxi China
  5. Department of Neurosurgery Penn State University‐Milton S. Hershey Medical Center Hershey Pennsylvania United States
  6. Department of Public Health Sciences Penn State University‐Milton S. Hershey Medical Center Hershey Pennsylvania United States
  7. Department of Neurology Penn State University‐Milton S. Hershey Medical Center Hershey Pennsylvania United States; Department of Pharmacology Penn State University‐Milton S. Hershey Medical Center Hershey Pennsylvania United States; Department of Radiology Penn State University‐Milton S. Hershey Medical Center Hershey Pennsylvania United States; Department of Neurosurgery Penn State University‐Milton S. Hershey Medical Center Hershey Pennsylvania United States; Department of Kinesiology Penn State University‐Milton S. Hershey Medical Center Hershey Pennsylvania United States
Abstract

Background: Susceptibility MRI may capture Parkinson's disease‐related pathology. This study delineated longitudinal changes in different substantia nigra regions.

Methods: Seventy‐two PD patients and 62 controls were studied at both baseline and after 18 months with MRI. R2* and quantitative susceptibility mapping values from the substantia nigra pars compacta and substantia nigra pars reticulata were calculated. Mixed‐effects models compared controls with PD or PD subgroups having different disease durations: early (<1 year), middle (<5 years, middle‐stage PD), and late (>5 years, late‐stage PD). Pearson's correlation assessed associations between imaging and clinical measures.

Results: At baseline, R2* and quantitative susceptibility mapping were higher in both the substantia nigra pars compacta and substantia nigra pars reticulata in all PD patients (group effect, P  ≤ 0.003). Longitudinally, the substantia nigra pars compacta R2* showed a faster increase in PD compared with controls (time × group, P  = 0.002), whereas quantitative susceptibility mapping did not ( P  = 0.668). The substantia nigra pars reticulata R2* and quantitative susceptibility mapping did not differ between PD and controls (time × group, P  ≥ 0.084), although both decreased longitudinally (time effect, P  ≤ 0.004). Baseline substantia nigra pars compacta R2* was higher in all PD subgroups (group, P  ≤ 0.006), but showed a significantly faster increase only in later‐stage PD (time × group, P  < 0.0001) that correlated with changes in nonmotor symptoms ( r  = 0.746, P  = 0.002). Baseline substantia nigra pars reticulata quantitative susceptibility mapping was higher in middle‐stage PD and later‐stage PD (group, P  ≤ 0.002), but showed a longitudinal decrease (time × group, P  = 0.004) only in later‐stage PD that correlated with changes in motor signs ( r  = 0.837, P  < 0.001).

Conclusion: Susceptibility MRI revealed distinct patterns of PD progression in the substantia nigra pars compacta and substantia nigra pars reticulata. The different patterns are particularly clear in later‐stage patients. These findings may resolve past controversies and have implications in the pathophysiological processes during PD progression. © 2018 International Parkinson and Movement Disorder Society

Sponsoring Organization:
USDOE
OSTI ID:
1437062
Journal Information:
Movement Disorders, Journal Name: Movement Disorders Journal Issue: 9 Vol. 33; ISSN 0885-3185
Publisher:
Wiley Blackwell (John Wiley & Sons)Copyright Statement
Country of Publication:
Country unknown/Code not available
Language:
English

References (39)

Neuroimaging biomarkers for Parkinson disease: Facts and fantasy: Neuroimaging Biomarkers for PD journal November 2014
Rate of progression in Parkinson's disease: A 6-[18F]fluoro-L-dopa PET study journal January 2001
Imaging nigral pathology and clinical progression in Parkinson's disease journal September 2012
Quantitative susceptibility mapping of the midbrain in Parkinson's disease: Nigral Iron in PD journal September 2015
The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward: MRI in Parkinsonian Disorders journal March 2017
Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes: R2* and QSM Reflect Pathology in Parkinsonism journal May 2018
Iron in parkinsonian and control substantia nigra?A m�ssbauer spectroscopy study journal January 1996
Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker: QSM journal July 2014
Contributions to magnetic susceptibility of brain tissue: Magnetic Susceptibility of Brain Tissue journal May 2016
Substantia Nigra Pars Reticulata Neurons in Parkinson's Disease journal March 1996
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain journal October 1988
The pattern of gray matter atrophy in Parkinson’s disease differs in cortical and subcortical regions journal October 2015
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study journal November 2010
Imaging Brain Iron and Diffusion Patterns journal January 2014
Imaging iron stores in the brain using magnetic resonance imaging journal January 2005
A reproducible evaluation of ANTs similarity metric performance in brain image registration journal February 2011
Susceptibility phase imaging with comparison to R2* mapping of iron-rich deep grey matter journal July 2011
Longitudinal midbrain changes in early Parkinson's disease: Iron content estimated from R2*/MRI journal March 2015
Magnetic resonance imaging as a potential biomarker for Parkinson's disease journal September 2016
Stability of R2* and quantitative susceptibility mapping of the brain tissue in a large scale multi-center study journal March 2017
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease journal July 2014
Caffeine Intake, Smoking, and Risk of Parkinson Disease in Men and Women journal April 2012
Ageing and Parkinson'S Disease: Substantia Nigra Regional Selectivity journal January 1991
Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature journal August 2010
Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease journal July 2013
Longitudinal changes in free-water within the substantia nigra of Parkinson’s disease journal May 2015
Progression marker of Parkinson’s disease: a 4-year multi-site imaging study journal July 2017
Unified Parkinson’s Disease Rating Scale-Motor Exam: inter-rater reliability of advanced practice nurse and neurologist assessments: Neurological assessment inter-rater reliability journal April 2010
Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease journal June 1989
Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X-Ray Microanalysis journal February 1991
Parkinson's disease beyond 20 years journal October 2014
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. journal March 1992
Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease journal May 2015
The Relevance of Iron in the Pathogenesis of Parkinson's Disease journal March 2004
[99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease journal May 2005
Midbrain iron content in early Parkinson disease: A potential biomarker of disease status journal January 2008
Is R2* a New MRI Biomarker for the Progression of Parkinson’s Disease? A Longitudinal Follow-Up journal March 2013
Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson’s Disease Stages? journal April 2016
Cognitive Impairments in Early Parkinson's Disease Are Accompanied by Reductions in Activity in Frontostriatal Neural Circuitry journal July 2003

Similar Records

Imaging Parkinsonian Pathology in Substantia Nigra with MRI
Journal Article · Sun Apr 15 00:00:00 EDT 2018 · Current Radiology Reports · OSTI ID:22876197

Differential loss of striatal projection neurons in Huntington disease
Journal Article · Mon Aug 01 00:00:00 EDT 1988 · Proceedings of the National Academy of Sciences of the United States of America; (USA) · OSTI ID:5404940

X-Ray Fluorescence Imaging: A New Tool for Studying Manganese Neurotoxicity
Journal Article · Sun Nov 18 19:00:00 EST 2012 · PLoS ONE · OSTI ID:1627557

Related Subjects